You just read:

New Phase 4 Study Shows Higher Rates of Clinical and Microbiological Success for Zyvox Versus Vancomycin in MRSA Nosocomial Pneumonia

News provided by

Pfizer Inc.

Oct 21, 2010, 07:00 ET